A61K 31/519
Ortho- or peri-condensed with heterocyclic rings
Official title: ortho- or peri-condensed with heterocyclic rings
A61K31/519 (Ortho- or peri-condensed with heterocyclic rings) appears on 10,365 US grants and 20,901 published applications in this corpus.
Search patents in A61K- Granted patents
- 10,365
- Published applications
- 20,901
- Assignees
- 5,797
- Inventors
- 34,802
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 9 | 0 |
| 1977 | 6 | 0 |
| 1978 | 2 | 0 |
| 1979 | 6 | 0 |
| 1980 | 5 | 0 |
| 1981 | 11 | 0 |
| 1982 | 8 | 0 |
| 1983 | 10 | 0 |
| 1984 | 10 | 0 |
| 1985 | 16 | 0 |
| 1986 | 11 | 0 |
| 1987 | 12 | 0 |
| 1988 | 21 | 0 |
| 1989 | 25 | 0 |
| 1990 | 21 | 0 |
| 1991 | 17 | 0 |
| 1992 | 26 | 0 |
| 1993 | 24 | 0 |
| 1994 | 19 | 0 |
| 1995 | 33 | 0 |
| 1996 | 46 | 0 |
| 1997 | 63 | 0 |
| 1998 | 69 | 0 |
| 1999 | 89 | 0 |
| 2000 | 108 | 0 |
| 2001 | 134 | 35 |
| 2002 | 135 | 201 |
| 2003 | 127 | 381 |
| 2004 | 105 | 404 |
| 2005 | 98 | 448 |
| 2006 | 151 | 488 |
| 2007 | 91 | 432 |
| 2008 | 103 | 416 |
| 2009 | 134 | 437 |
| 2010 | 185 | 486 |
| 2011 | 180 | 531 |
| 2012 | 241 | 544 |
| 2013 | 311 | 732 |
| 2014 | 426 | 956 |
| 2015 | 562 | 1025 |
| 2016 | 593 | 1125 |
| 2017 | 696 | 1137 |
| 2018 | 651 | 1078 |
| 2019 | 738 | 1199 |
| 2020 | 686 | 1156 |
| 2021 | 645 | 1218 |
| 2022 | 621 | 1290 |
| 2023 | 498 | 1323 |
| 2024 | 582 | 1406 |
| 2025 | 592 | 1361 |
| 2026 | 413 | 1092 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- MRGX receptor antagonists6 Oct 2026US 12,751,953 B2Katholieke Universiteit Leuven of KU Leuven Research & Development
- Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds6 Oct 2026US 12,751,954 B2Principia Biopharma Inc.
- Spirotricycle RIPK1 inhibitors and methods of uses thereof6 Oct 2026US 12,753,190 B2Merck Sharp & Dohme Corp.
- Method of predicting therapeutic response and prognosis of metastatic breast cancer to chemotherapeutic agents, and treating metastatic breast cancer6 Oct 2026US 12,753,447 B2Samsung Life Public Welfare Foundation
- Long acting injectable formulation comprising risperidone and biodegradable polymers29 Sep 2026US 12,746,197 B2Medincell
- Tea compositions comprising paraxanthine and methods of production thereof8 Oct 2026US 2026/0305643 A1
- Methods of preventing post-traumatic osteoarthritis using metformin8 Oct 2026US 2026/0306428 A1
- Compositions, Kits, and Methods Comprising Bioidentical D BHB With Optional Vitamin B6 for Neurological Wellness, Mood Stability, and Medication Taper Support8 Oct 2026US 2026/0306430 A1Global Ketone Limited
- Nutritional compositions, supplements, and fortifiers8 Oct 2026US 2026/0306432 A1Societe des Produits Nestle S. A.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
Most cited
By later US patents
- Wound dressing with conformable elastomeric wound contact layer1,263US 5,445,604 ASmith and Nephew Associated Companies Limited · 1995
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine486US 10,299,720 B2The General Hospital Corporation · 2019
- Controlled-release formulations coated with aqueous dispersions of ethylcellulose445US 5,472,712 AEuroceltique, S.A. · 1995
- Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer438US 5,273,760 AEuroceltigue, S.A. · 1993